Atlas Trials

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma

Clinical trial NCT04975399 · TERMINATED

Trial details

NCT number
NCT04975399
Sponsor
Celgene
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2021-10-05
Primary completion
2024-06-18
Enrollment
26

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.